Balkrishna Industries Ltd.

All figures are consolidated, in INR crore, for fiscal years ended 31 March, sourced from the company's audited results as compiled by Screener/C-MOTS from BSE filings, cross-checked against CRISIL's Key Financial Indicators (which report FY2025 operating income of INR 10,447 crore and PAT of INR 1,655 crore, matching) and against the company's own FY2026 results release (consolidated revenue from operations INR 10,823.08 crore; total income INR 11,074.91 crore; PAT INR 1,243.10 crore; EPS INR 64.30).

Profit and loss: notes and sources

USD conversions use indicative period-average rates of approximately 74.5, 80.4, 82.8, 84.6 and 87.5 INR/USD respectively. These are analyst conversions, not company disclosures.

Margins: notes and sources

Note on definitional divergence: CRISIL reports an FY2025 EBITDA margin of 26.2% and FY2024 of 25.0%, using a standalone-adjusted definition that differs from the consolidated operating-profit basis above. Both are internally consistent within their own frames; the directional story — a peak in FY2024–FY2025 and compression in FY2026 — is identical.

Balance sheet: notes and sources

Long-term versus short-term debt split is not fully disclosed at consolidated level in the sources reviewed. CRISIL states long-term debt of approximately INR 722 crore as of March 2025. Total rated bank facilities stand at INR 2,000 crore, comprising cash credit INR 20 crore, letters of credit and bank guarantees INR 265 crore, packing credit INR 730 crore, short-term facilities INR 265 crore, term loans INR 338 crore (Kotak INR 120 crore, Standard Chartered INR 18 crore, Shinhan INR 200 crore as of August 2026) and proposed long-term facilities INR 382 crore. Commercial paper programme: INR 500 crore. NCDs: INR 750 crore rated February 2026, plus a further INR 550 crore approved and allotted in three series in August–September 2026.

Goodwill and intangibles are not separately disclosed in the compiled consolidated balance sheet reviewed. BKT has made no material acquisitions, so goodwill is expected to be immaterial.

The company's own Q1 FY2027 balance-sheet slide gives March 2026 total assets of INR 17,713 crore, equity of INR 10,966 crore and total liabilities of INR 6,747 crore, versus March 2025 of INR 15,560 crore, INR 10,384 crore and INR 5,176 crore respectively — marginally different from the filed consolidated figures above, likely a standalone-versus-consolidated presentation difference. Both are shown.

Cash flow: notes and sources

No share buyback has been undertaken or authorised in the period reviewed.

Returns and efficiency ratios: notes and sources

CRISIL reports interest coverage of 22.7x for FY2025 and 23.9x for FY2024, and adjusted debt/net worth of 0.31x and 0.35x. The coverage divergence is definitional — CRISIL appears to include other income and use EBITDA rather than EBIT. Adjusted leverage matches exactly. Current ratio is not derivable from the summarised balance sheet reviewed, since current and non-current assets are not separated in the compiled presentation.

Commentary: trends, inflections and drivers

FY2022 — the post-Covid peak. Revenue jumped 43% on a combination of volume recovery, aggressive pricing and favourable geographic mix, with Europe at 54% of revenue. EBITDA margin of 24% understates the year's quality; on CRISIL's standalone-adjusted basis, operating profitability reached 27%. Interest cover was effectively unbounded. This was the high-water mark for the export-centric, Europe-weighted model.

FY2023 — the margin shock. The defining inflection. Revenue grew 18% to INR 9,760 crore but EBITDA fell 15% and net profit fell 26%. The cause was mechanical: raw material and ocean freight costs rose faster than BKT could pass them on. CRISIL characterises this precisely — "operating profitability declined to 20% in fiscal 2023 from 27% in fiscal 2022, because of a lag in passing on rising input and ocean freight cost to customers." Simultaneously, borrowings rose from INR 2,529 crore to INR 3,347 crore as the Bhuj build-out and carbon black Phase 2 consumed cash, pushing finance cost from INR 9 crore to INR 48 crore. ROCE collapsed from 24% to 14%. This year established the central vulnerability of the franchise: it is a price-taker on input and a price-setter only with a lag.

FY2024 — margin recovery on falling revenue. An unusual year. Revenue declined 4% to INR 9,369 crore as European destocking bit, yet EBITDA rose 32% and net profit 39%. Raw material deflation and freight normalisation flowed straight through. This demonstrates the operating leverage in reverse: BKT's earnings are far more sensitive to input cost than to volume. Free cash flow turned strongly positive at INR 1,001 crore as capex fell to approximately INR 1,081 crore.

FY2025 — peak earnings. Revenue of INR 10,447 crore (+11.5%) and PAT of INR 1,655 crore, the highest in company history, with EPS of INR 85.61. CRISIL's EBITDA margin of 26.2% marks the profitability peak. Notably, the market did not reward it — the stock fell 7.4% on the result as EPS missed consensus by 3.1%, and the consensus price target was cut 6.5% to INR 2,628. Net debt was effectively nil.

FY2026 — the tariff and mix year. Revenue grew only 3.6% to INR 10,823 crore while PAT fell 24.9% to INR 1,243 crore and EPS to INR 64.30. Three forces converged. First, the United States imposed cumulative 50% tariffs on Indian goods from late August 2025, with BKT's Americas volumes falling in double digits and the company absorbing part of the duty. Second, European demand remained weak on farmer income pressure and falling soft-commodity prices, though it recovered sequentially through H2 as destocking eased. Third — and structurally most important — the geographic mix shifted decisively toward India (23% growth in 9M FY2026), which carries a lower average selling price and therefore dilutes margin even as it adds volume. Management confirmed this directly in Q1 FY2027: "India's contribution has increased to overall 40% of the volumes, which has impacted the margin slightly."

The FY2026 balance sheet tells the strategic story more clearly than the P&L. CWIP surged from INR 986 crore to INR 2,472 crore and derived capex reached approximately INR 2,998 crore — the largest single-year investment in company history. Borrowings rose from INR 3,267 crore to INR 4,111 crore. Free cash flow swung to negative INR 749 crore. ROCE fell to 11%, the lowest in the decade reviewed. This is not deterioration; it is a company deliberately front-loading a capital cycle. But it means reported returns will remain depressed until the INR 6,800 crore programme starts generating revenue.

Q1 FY2027 — early evidence the cycle is turning. Record volumes of 93,770 MT (+16%), consolidated revenue of INR 3,455 crore (+25%), consolidated PAT of INR 451 crore (+61%), consolidated EBITDA margin of 21.53% versus 18.34%. The standalone presentation shows margin compressing 315 basis points to 20.61% — a genuine reporting inconsistency across the company's own disclosures that management did not reconcile on the call. The most defensible reading is that consolidated margin expanded against a weak base quarter while standalone margin compressed against a stronger standalone base. Raw material cost rose to INR 1,935 crore from INR 1,285 crore, and a realised forex loss of INR 36 crore (versus INR 1 crore) weighed on the result.

Management guidance and targets

Rating agency and consensus expectations

There is a material and unresolved gap between management's 23–25% margin target and CRISIL's 20–23% base case, attributable entirely to how each party weights the dilution from India mix, on-highway entry and merchant carbon black. This gap is the single most important variable for the equity.

Bull case

1. The volume cycle has demonstrably turned, and the market has not paid for it. Q1 FY2027 delivered 93,770 MT, the highest quarterly volume in company history, up 16.2% year on year, following record Q4 FY2026 volumes of 85,820 MT. Consolidated revenue grew 25.2% and consolidated PAT 61%. Yet the stock trades 9% below where it stood a year ago and 22% below its 52-week high. If FY2027 volumes annualise anywhere near the Q1 run rate, revenue of INR 13,500–14,000 crore is achievable against a market currently pricing continued stagnation. Consensus price targets have been cut five times in eighteen months into an accelerating operating performance.

2. Backward integration is complete and starts paying now, not later. The INR 925 crore carbon black and power programme is finished and funded from internal accruals: 360,000 MTPA of carbon black including 30,000 MTPA of advanced grades, and 64 MW of off-gas co-generation. Management estimates 150–200 basis points of margin benefit from full backward integration, and off-gas already supplies approximately 60% of total energy. This capex is behind the company, in the depreciation base, and about to be reflected in gross margin. It also generates a merchant revenue line already at ~10% of sales that is structurally uncorrelated with the agricultural cycle.

3. The tariff shock is reversing and the US is the largest untapped share opportunity. BKT holds 3–4% share in the United States against 18–19% in India. The 50% tariff that compressed FY2026 has reduced toward 15–18%, US volumes recovered 11% sequentially in Q3 FY2026, and the company has filed for refunds on duties already paid — an unquantified but strictly positive option. If US share moves from 3.5% toward even the European level of 7.5%, that alone is worth several hundred crore of high-margin export revenue with no incremental capacity required, since the 425,000 MTPA roadmap is already funded.

Bear case

1. Return on capital has halved and the strategy makes it worse before it makes it better. ROCE fell from 24% in FY2022 to 11% in FY2026; three-year average ROE is 13.2%; FY2026 ROE on average equity was 11.6%. Meanwhile CWIP more than doubled to INR 2,472 crore, borrowings rose 26% to INR 4,111 crore, and free cash flow swung to negative INR 749 crore with FY2027 capex guided at INR 2,500–3,000 crore. The company is deploying INR 6,800 crore into a business whose incremental mix — India OHT, Indian on-highway, merchant carbon black — is uniformly lower-margin than the Europe-weighted export base it is replacing. On CRISIL's own numbers, steady-state margin settles at 20–23% versus the 26.2% achieved in FY2025. A structurally lower-margin, more capital-intensive business deserves a lower multiple than 29.8× earnings and 3.82× book.

2. Over 40% of the FY2030 growth target depends on a business BKT has never operated. Reaching INR 23,000 crore requires roughly 17% compound growth from a base that grew 3.6% last year, and INR 5,000 crore of the increment is meant to come from Indian on-highway tyres. In that market BKT has no dealer network, no brand equity, no cost advantage, and none of its actual competitive strengths transfer — catalogue breadth, small-lot service and OHT OEM approvals are worthless against MRF, CEAT, Apollo and JK Tyre in a scale-driven commodity segment. Management's own language is telling: FY2027 is "a year of building the portfolio," with distribution built "in a phased manner rather than pursuing aggressive expansion." That is the correct operational posture and it is fundamentally incompatible with the arithmetic of the FY2030 target.

3. The margin model is structurally fragile and the fragility is recurring, not historical. Raw materials are approximately 70% of production cost, approximately 50% is imported, and the entire borrowing book is in foreign currency. FY2023 showed what happens when input costs move faster than pricing: operating margin fell from 27% to 20% and net profit fell 26% on 18% revenue growth. The same mechanism is operating right now — Q1 FY2027 raw material cost of INR 1,935 crore against INR 1,285 crore, a realised forex loss of INR 36 crore, and management guiding to approximately 2% further margin compression in Q2 with more in Q3. The company has never demonstrated the ability to hold margin through an input-cost upcycle, and it is entering one with materially higher leverage than it carried in FY2023.

Catalysts and monitorables — next twelve months

Analyst verdict

Balkrishna Industries is a genuinely high-quality industrial franchise passing through the least attractive phase of a deliberate strategic transition, and the equity is priced as though the transition is already de-risked.

The quality is real and should not be understated. Eight of nine years above 24% operating margin, a backward-integration position no comparable-sized competitor can match, a 3,600-SKU catalogue that constitutes a genuine barrier, dual AA+ ratings sustained through a 50% tariff shock, an immovable promoter holding with no pledging, zero fatalities for three years, and OEM validation from Deere, Caterpillar and CNH. Q1 FY2027 delivered the best volume quarter in the company's history. None of that is in dispute.

What is in dispute is whether the business BKT is building will earn what the business BKT built used to earn. The evidence says no, and management's own numbers concede as much: FY2030 revenue mix of 70% OHT, 20% on-highway and 10% carbon black is, line by line, a mix shift away from the highest-margin activity toward two lower-margin ones. CRISIL — which has every reason to be constructive, having just upgraded the credit — models steady-state margin at 20–23% against management's 23–25%, explicitly citing "the increasing share of new lower-margin businesses." Return on capital employed at 11% is not a cyclical trough; it is what a capital-intensive company earns while spending INR 6,800 crore, and it will not recover to 24% because the returns on the incremental capital are structurally lower than the returns on the installed base.

The valuation does not reflect this. At 29.8× trailing earnings and 3.82× book with three-year ROE of 13.2%, negative five-year profit CAGR and negative three-year share price CAGR, the market is paying a growth multiple for a business currently generating value-stock returns. The sell side has recognised the problem — targets cut from INR 2,874 to roughly INR 2,300–2,450 over eighteen months, with two named houses at Sell and Reduce — but the multiple has not fully adjusted.

The pivotal question is not whether BKT can grow volumes; it demonstrably can. It is whether INR 5,000 crore of Indian on-highway revenue by FY2030 is a plan or an aspiration. On the evidence available — pilot sales only, phased distributor build, meaningful scaling deferred to FY2028, and competition against four entrenched domestic incumbents — it is an aspiration. Strip it out and the FY2030 target falls to roughly INR 18,000 crore, an 11% CAGR, which is credible and which the OHT and carbon black businesses can deliver on their own. That is the number to underwrite.

Position: a quality compounder in a value-destroying phase. The operating turn is real and arrived earlier than consensus expected; the return-on-capital turn is at least two years away and may never fully arrive. Constructive on the business, cautious on the multiple, and specifically sceptical of the on-highway component of the growth story. The monitorables that matter most are Q2 and Q3 FY2027 margin against the guided ~2% compression, FY2027 capex against the INR 2,500–3,000 crore guidance, and the first hard revenue disclosure from the on-highway segment.